Menu

Resident Faculty Research

At Rutgers Cancer Institute of New Jersey, scientific research goes beyond traditional microscopes and beakers. Our research members – whether basic scientists, bioinformatics specialists, statisticians, clinical specialists, population scientists, or others – have unique expertise in various translational aspects of cancer research. They work collaboratively to translate the latest innovations in cancer research into tomorrow’s treatments for cancer patients.

White Laboratory

Current research of the White Laboratory at Rutgers Cancer Institute of New Jersey has focused on translational research modulating the apoptosis pathway for cancer therapy and on the role of autophagy and cellular metabolism in cancer progression and treatment.


Bandera Research Program

Dr. Elisa V. Bandera is an epidemiologist at Rutgers Cancer Institute of New Jersey and her research and training program focuses on the role of nutritional, hormonal, and other lifestyle factors play on cancer prevention and survival. She is also interested in early determinants of breast cancer risk.
 

Carpizo Laboratory

The Carpizo Laboratory studies cancer biology of gastrointestinal cancers with an emphasis on developmental therapeutics. Studies range from basic biology to provide clues for novel therapies, to translational research projects to move forward exciting new technologies for cancer treatment.


Chan Laboratory

Dr. Chan’s lab is interested in understanding the role of p53 in cancer, and focuses on cancer genomics, cancer evolution and resistance to therapy, and gene regulation.


De Laboratory

The cancer genome informatics group, headed by Dr. Subhajyoti De, develops and applies novel genomics methods and computational toolsets to understand the hallmarks of cancer, and use that knowledge for better diagnosis, stratification, and treatment of this disease.


Drake Laboratory

The Drake Laboratory studies advanced prostate cancer and how new targeted therapies can be identified and tested in this disease. Using approaches from mass spectrometry to in vivo experimental models, the Drake Lab investigates how kinases can be effectively identified and targeted for personalized medicine.
 

Evens Laboratory

The Evens Laboratory studies complex cell-cell and signaling pathway connectivity interactions with the aim of improving lymphoma prognosis and treatment through: 1) development of new and innovative targeted cancer therapeutics, 2) investigation of biologic aspects of the immune system through novel microfluidic and single cell technology, and 3) discovery of "omic" biomarkers of efficacy and resistance to cancer therapeutics. 


Zhaohui Feng Laboratory

The Feng Laboratory studies the role of p53 in regulating cellular metabolism and how this contributes to tumor suppression. We are also interested in identifying new regulators and regulation mechanisms for p53 and its signaling pathway, and studying how mutant p53 can be targeted for cancer therapy. We also examine the mechanism of metabolic reprogramming in cancer and how metabolic changes in cancer can be targeted for therapy.


Foran Laboratory

One of the goals of Dr. Foran's laboratory research is to develop a set of algorithms and software tools which facilitate automated imaging, analysis, and archiving of tumor tissue microarrays. In doing so, Dr. Foran's laboratory is currently working to determine the relationship between tumor image analysis-derived information and molecular status/clinical outcome in a way that will permit researchers to systematically carry out large-scale comparative analyses of human cancers.
 

Ganesan Laboratory

The Ganesan Laboratory investigates the role of DNA repair defects in cancer, with a focus on how disruption of BRCA1-dependent DNA repair pathways affects normal DNA repair choice, and leads to both genomic instability and epigenetic instability.


Guo Laboratory

Research in the Guo Lab focuses on the field of cancer metabolism, with an emphasis on how autophagy is involved in modulating cancer metabolism to maintain Kras-driven lung tumor growth and metastasis.
 

Gatza Laboratory

The Gatza Laboratory leverages cancer genomics and bioinformatics with experimental molecular biology and genetics to identify and elucidate mechanisms of oncogenic signaling and cancer genesis as a means to further understand breast and ovarian tumor biology and to develop personalized cancer therapies.
 

Haffty Laboratory

Research in the Haffty laboratory at Rutgers Cancer Institute focuses on translational investigation of combining radiation therapies with novel drugs targeting breast cancer and other cancers.


Herranz Laboratory

The Herranz Lab aims to discover and define how oncogenic and tumor suppressor enhancers impact tumorigenesis in hematological and solid tumors, and to dissect the interplay between cancer cell-specific metabolic rewiring and epigenetics in T-cell Acute Lymphoblastic Leukemia (T-ALL).


Wenwei Hu Laboratory

The research interest of Dr. Hu's laboratory is to understand the alteration of important cancer-related signaling pathways in tumorigenesis, including the p53 and LIF signaling.


Khiabanian Laboratory

The Khiabanian Laboratory develops mathematical methods and employs high-throughput genomics techniques to understand the underlying genetics of human malignancies and the molecular epidemiology of disease-causing organisms, especially to study the evolution of clonal expansions in the context of disease transformation and relapse.
 

Isaac Kim Laboratory

The research interests of Dr. Kim's laboratory focus on uncovering molecular mechanisms that govern sensitivity and resistance to anti-androgen therapy in prostate cancer and renal cell carcinoma.


Lattime Laboratory

The focus of the Lattime Lab lies in the interrogation of the tumor-host immune interaction both systemic and in the tumor microenvironmemnt and, based on preclinical models, the development and testing of novel immunotherapeutic modalities in early phase clinical trials.


Pine Laboratory

The Pine lab focuses on stem cell signaling pathways that drive lung carcinogenesis, lung tumor progression, and resistance to therapy.


Sabaawy Laboratory

Led by Dr. Hatem Sabaawy, investigators at the Cancer Institute's zebrafish laboratory use zebrafish models to map the common genetic defects in cancer, identify new small molecules for targeted treatment, and predict each cancer patient's response to therapy in precision medicine trials. Among other applications, learn how zebrafish research is helping in the fight against prostate cancer. 


Shen Laboratory

Current research of the Shen Laboratory focuses the mechanisms by which genomic instability is provoked during tumorigenesis. Using a BRCA2 interacting protein BCCIP and its associated protein network as the platform, we investigate the roles of mammalian homologous recombination (HR) in error-less DNA repair, replication fidelity, and precise mitotic cell division.


Xia Laboratory

Research in the Bing Xia Laboratory is focused on the roles of DNA damage, oxidative stress and autophagy in cancer development. Much of our research program originated from our discovery of the PALB2 tumor suppressor, which functionally links BRCA1 and BRCA2, the two major breast cancer suppressor proteins in the DNA damage response. 


Zheng Laboratory

The Zheng Laboratory is interested in the mechanisms of nutrient signaling that control growth and metabolism, their contributions to cancer and diseases such as diabetes and hepatic steatosis, and development of novel therapeutic strategies.


Zloza Laboratory

The Zloza Laboratory focuses on understanding the interplay between infections, cancer, and the immune system.


Center for Systems and Computational Biology (CSCB)

The research at the Center for Systems and Computational Biology focuses on cancer genomics and translational medicine, particularly developing novel quantitative and experimental approaches to discover disease-driving aberrations, understand cancer pathogenesis, improve diagnosis, and design effective clinical trials and precise treatment strategies for patients under active care.

 

precision medicine at Rutgers Cancer Institute

 

 

 

ScreenNJ

 

 

Donate Now

 

 

 


 

 

 

 

Proud member of
Big Ten Cancer Research Consortium

 

 

Rutgers Health